Siplizumab in T1DM
Public ClinicalTrials.gov record NCT05574335. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A T Cell Phenotype Signature Driven Dose Finding Study With Siplizumab in Type 1 Diabetes Mellitus (ITN095AI)
Study identification
- NCT ID
- NCT05574335
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Enrollment
- 8 participants
Conditions and interventions
Conditions
Interventions
- Siplizumab Drug
Drug
Eligibility (public fields only)
- Age range
- 8 Years to 45 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 25, 2023
- Primary completion
- May 13, 2025
- Completion
- Oct 19, 2025
- Last update posted
- Feb 10, 2026
2023 – 2025
United States locations
- U.S. sites
- 5
- U.S. states
- 5
- U.S. cities
- 5
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Colorado School of Medicine: Barbara Davis Center for Diabetes | Aurora | Colorado | 80045 | — |
| University of Iowa Children's Hospital: Department of Pediatrics, Pediatric Endocrinology and Diabetes | Iowa City | Iowa | 52242 | — |
| Columbia University Medical Center: Naomi Berrie Diabetes Center | New York | New York | 10032 | — |
| University of Texas Southwestern Medical Center: Department of Internal Medicine, Division of Endocrinology | Dallas | Texas | 75390 | — |
| Benaroya Research Institute at Virginia Mason: Diabetes Research Program | Seattle | Washington | 98101 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05574335, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 10, 2026 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05574335 live on ClinicalTrials.gov.